Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05656196
Other study ID # 2022-08-011A
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2023
Est. completion date December 31, 2023

Study information

Verified date January 2024
Source Taipei Veterans General Hospital, Taiwan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the Chinese herbal tea VGH-DESJS-1 in ocular and oral dryness symptoms of Dry eye syndrome and Sjögren's syndrome


Description:

Method: This study wants to evaluate the Chinese herbal tea VGH-DESJS-1 on Nourishing Yin and Moistening Dryness the ocular dryness from dry eye syndrome (DES) and Sjögren's syndrome (SJS). One hundred dry eye subjects are composed of 30 dry eye syndrome subjects, 60 Sjögren's syndrome' dry eye subjects, and 10 non DES SJS Healthy Controls, NHC). DES, SJS, and NHC received VGH-DESJS-1 daily during 8 weeks for the evaluation before and after the subjects receiving the VGH-DESJS-1. Moreover, we could use the Whole-genome genotyping, Schirmer's test, Tear breakup time (TBUT), Cytokines, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), Traditional Chinese Medicine (TCM) pattern, TCM tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability, and it could be applied for the goal of holistic health care. Expected Results: 1. To evaluate the difference among Schirmer's test, TBUT, TCM pattern, TCM tongue diagnosis, TCM pulse diagnosis, heart rate variability, Whole-genome genotyping, and Cytokines for DES, SJS, and NHC. 2. To evaluate the Nourishing Yin and Moistening Dryness of VGH-DESJS-1 for DES and SJS. 3. To evaluate the Nourishing Yin and Moistening Dryness of VGH-DESJS-1 for DES. 4. To evaluate the Nourishing Yin and Moistening Dryness of VGH-DESJS-1 for SJS. Keywords: Dry eye syndrome, Sjögren's syndrome, Xerophthalmia, Chinese herbal tea, Nourishing Yin and Moistening Dryness


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 31, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 75 Years
Eligibility Dry eye syndrome -Inclusion Criteria: aged between 20 and 75 years Schirmer's test less than 10 mm/5 min -Exclusion Criteria: Pregnancy With eye inflammation or infectious eye disease Accepted operation of eye Sjögren's syndrome -Inclusion Criteria: primary or secondary SS aged between 20 and 75 years fulfilled the 2002 American-European Consensus Criteria for SS (AECG) had no abnormal findings of immune, liver, kidney, or blood function evaluations. -Exclusion Criteria: a history of alcohol abuse, diabetes mellitus, or major life-threatening condition pregnancy or breastfeeding steroid pulse therapy within three months prior to the commencement of our study. non AIDDES Healthy Controls -Inclusion Criteria: aged between 20 and 75 years without any Chronic disease -Exclusion Criteria: any Sjögren's syndrome or Dry eye syndrome.

Study Design


Intervention

Other:
Chinese herbal tea VGH-DESJS-1
Chinese herbal tea VGH-DESJS-1.

Locations

Country Name City State
Taiwan Ching-Mao Chang Taipei

Sponsors (1)

Lead Sponsor Collaborator
Taipei Veterans General Hospital, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Schirmer's test Dry eye syndrome (DES) and Sjögren's syndrome (SJS) take the Schirmer's test. 8 weeks
Primary Ocular Surface Disease Index (OSDI) Dry eye syndrome (DES) and Sjögren's syndrome (SJS) take the OSDI(Ocular Surface Disease Index). 8 weeks
Secondary TCM pattern Dry eye syndrome (DES), Sjögren's syndrome (SJS), and on DES SJS Healthy Controls (NHC) take the TCM pattern to differentiate the 9 types of TCM constitutions. 8 weeks
Secondary TCM tongue diagnosis Dry eye syndrome (DES), Sjögren's syndrome (SJS), and on DES SJS Healthy Controls (NHC) take the TCM tongue diagnosis with camera photo to differentiate the TCM tongue feature factors about Tongue body, Tongue Coating, Red spot, Tooth marks, and Ecchymosis. TCM tongue feature factors would present the status of inflammation, blood stasis, heat, dampness with TCM theory. 8 weeks
Secondary TCM pulse diagnosis Dry eye syndrome (DES), Sjögren's syndrome (SJS), and on DES SJS Healthy Controls (NHC) take the TCM pulse diagnosis with blood pressure monitors to differentiate the TCM pulse feature factors about Floating, Deep, Slow, Rapid, Deficient, Excessive, Slippery, Rough, String-like, Soggy, Fine, Weak. TCM tongue feature factors would present the status of inflammation, blood stasis, heat, dampness with TCM theory. 8 weeks
Secondary TCM heart rate variability Dry eye syndrome (DES), Sjögren's syndrome (SJS), and on DES SJS Healthy Controls (NHC) take the TCM heart rate variability. 8 weeks
Secondary Whole-genome genotyping(TWBv2.0) Dry eye syndrome (DES), Sjögren's syndrome (SJS), and on DES SJS Healthy Controls (NHC) take the Whole-genome genotyping (TWBv2.0). 8 weeks
Secondary Cytokine markers Dry eye syndrome (DES), Sjögren's syndrome (SJS), and on DES SJS Healthy Controls, NHC) take the cytokine markers (IL-17, MMP-9, BAFF, BCMA) analysis. 8 weeks
Secondary Pittsburgh Sleep Quality Index Dry eye syndrome (DES), Sjögren's syndrome (SJS), and on DES SJS Healthy Controls, NHC) take the Pittsburgh Sleep Quality Index 8 weeks
Secondary Ford Insomnia Response to Stress Test Dry eye syndrome (DES), Sjögren's syndrome (SJS), and on DES SJS Healthy Controls, NHC) take the Ford Insomnia Response to Stress Test. 8 weeks
Secondary EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) Dry eye syndrome (DES), Sjögren's syndrome (SJS), and on DES SJS Healthy Controls, NHC) take the EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT04968912 - A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) Phase 2
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT00809003 - Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease N/A
Completed NCT00023491 - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells N/A
Completed NCT05005806 - Fish Oil (Omega 3 ) in Sjogren's Syndrome Phase 2/Phase 3
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Terminated NCT04143841 - Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease N/A
Completed NCT03611283 - Topical Management of Xerostomia With Dry Mouth Products N/A
Recruiting NCT06104124 - A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Phase 3
Recruiting NCT05115487 - Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
Recruiting NCT06437652 - An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
Recruiting NCT05383677 - Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT03938207 - Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
Completed NCT04546542 - Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT05085431 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome Early Phase 1
Completed NCT00565526 - Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
Completed NCT01369589 - An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness Phase 1/Phase 2
Completed NCT00001953 - The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers N/A